Literature DB >> 1518040

In-vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents.

R Cedillo-Rivera1, O Muñoz.   

Abstract

The susceptibility of a strain of Giardia lamblia to benzimidazole carbamates, 5-nitroimidazoles, nitrofurans and other drugs was studied in vitro. Albendazole was the most active compound, with a 50% inhibitory concentration (IC50) of 0.01 mg/L and a minimal lethal concentration (MLC) of less than 0.04 mg/L; the IC50 of mebendazole was 0.06 mg/L and the MLC less than 0.5 mg/L. Among the 5-nitroimidazoles tested, ornidazole was the most effective (IC50 0.12 mg/L); tinidazole, metronidazole, secnidazole and hemezole were less active. Nifuroxazide, etofamide and nalidixic acid exhibited modest anti-giardial activity; quinfamide did not inhibit the growth of the parasite at a concentration of 200 mg/L. Albendazole and mebendazole are promising candidates for clinical use and should be further evaluated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1518040     DOI: 10.1099/00222615-37-3-221

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  23 in total

1.  High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.

Authors:  Catherine Z Chen; Liudmila Kulakova; Noel Southall; Juan J Marugan; Andrey Galkin; Christopher P Austin; Osnat Herzberg; Wei Zheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence.

Authors:  Yoalli Martínez-Pérez; Mario Nequiz-Avendaño; Itzhel García-Torres; Marco E Gudiño-Zayas; Gabriel López-Velázquez; Sergio Enríquez-Flores; Edith Mendoza; Emma Saavedra; Ruy Pérez-Tamayo; Gloria León-Avila; Alfonso Olivos-García
Journal:  Parasitol Res       Date:  2020-09-04       Impact factor: 2.289

3.  A new method for assessing metronidazole susceptibility of Giardia lamblia trophozoites.

Authors:  M C Sousa; J Poiares-Da-Silva
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

5.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

6.  A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis.

Authors:  Shahram Solaymani-Mohammadi; Jeanine M Genkinger; Christopher A Loffredo; Steven M Singer
Journal:  PLoS Negl Trop Dis       Date:  2010-05-11

7.  Giardia lamblia: a report of drug effects under cell differentiation.

Authors:  Moema A Hausen; Richard Pereira de Oliveira; Ana Paula Rocha Gadelha; Loraine Campanati; Jorge José de Carvalho; Laís de Carvalho; Helene Santos Barbosa
Journal:  Parasitol Res       Date:  2009-05-12       Impact factor: 2.289

8.  Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence.

Authors:  S K Katiyar; V R Gordon; G L McLaughlin; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Albendazole versus metronidazole treatment of adult giardiasis: An open randomized clinical study.

Authors:  Oguz Karabay; Ali Tamer; Huseyin Gunduz; Derya Kayas; Huseyin Arinc; Harika Celebi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

10.  Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia.

Authors:  Horacio Reyes-Vivas; Ignacio de la Mora-de la Mora; Adriana Castillo-Villanueva; Lilian Yépez-Mulia; Gloria Hernández-Alcántara; Rosalia Figueroa-Salazar; Itzhel García-Torres; Saúl Gómez-Manzo; Sara T Méndez; América Vanoye-Carlo; Jaime Marcial-Quino; Angélica Torres-Arroyo; Jesús Oria-Hernández; Pedro Gutiérrez-Castrellón; Sergio Enríquez-Flores; Gabriel López-Velázquez
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.